公司資料
Dyne Therapeutics 股價、新聞與催化劑
- 股票代碼:
- DYN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
26.10 USD (+0.46%)
收盤價
最後更新: 2026年8月21日
2.85B USD
市值
股價為何變動
The latest company update was “Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. DYN changed 0.46% and closed at $26.10 on Aug 21, 2026, indicating a relatively limited closing-price reaction to this company update.
公司概覽
Oligonucleotide Therapeutics
Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue.
Duchenne Muscular Dystrophy
Z-rostudirsen is designed for patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The candidate has completed the registrational portion of the DELIVER program, and Dyne is preparing it for regulatory submission and commercialization.
Myotonic Dystrophy
Z-basivarsen targets toxic DMPK RNA in myotonic dystrophy type 1. It is being evaluated in the Phase 1/2 ACHIEVE study and the global confirmatory Phase 3 HARMONIA trial.
未來催化劑
- BLA submission for z-rostudirsen in the second quarter of 2026.
- Completion of enrollment in the registrational ACHIEVE expansion cohort for z-basivarsen in the second quarter of 2026.
- Potential U.S. launch of z-rostudirsen in the first quarter of 2027, subject to approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。